Eric von Hofe - JoVE Visualize

Showing results (1-10 of 24) with videos related to

Pageof 3

Sort By:

Vaccine|March 6, 2012

CD4+ T-cell activation for immunotherapy of malignancies using Ii-Key/MHC class II epitope hybrid vaccinesMinzhen Xu, Nikoletta L Kallinteris, Eric von Hofe

Cellular & Molecular Immunology|October 13, 2005

Forcing tumor cells to present their own tumor antigens to the immune system: a necessary design for an efficient tumor immunotherapyRobert E Humphreys, Gilda G Hillman, Eric von Hofe, et al.

Vaccine|June 13, 2009

Ii-Key/HPV16 E7 hybrid peptide immunotherapy for HPV16+ cancersMinzhen Xu, Xueqing Lu, Margaret Sposato, et al.

Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 8, 2005

Enhanced CD4+ T-cell response in DR4-transgenic mice to a hybrid peptide linking the Ii-Key segment of the invariant chain to the melanoma gp100(48-58) MHC class II epitopeNikoletta L Kallinteris, Shuzhen Wu, Xueqing Lu, et al.

Vaccine|July 15, 2009

Identification of HLA class II H5N1 hemagglutinin epitopes following subvirion influenza A (H5N1) vaccinationJohn W Zinckgraf, Margaret Sposato, Veronica Zielinski, et al.

Expert Opinion on Biological Therapy|December 10, 2008

CD4+ T cells in antitumor immunity: utility of an li-key HER2/neu hybrid peptide vaccine (AE37)Elizabeth A Mittendorf, Jarrod P Holmes, James L Murray, et al.

Immunology|November 23, 2006

Suppression of major histocompatibility complex class II-associated invariant chain enhances the potency of an HIV gp120 DNA vaccineXueqing Lu, Shuzhen Wu, Catherine E Blackwell, et al.

Vaccine|March 10, 2005

Linkage of Ii-Key segment to gp100(46-58) epitope enhances the production of epitope-specific antibodiesNikoletta L Kallinteris, Shuzhen Wu, Xueqing Lu, et al.

Expert Opinion on Biological Therapy|January 17, 2007

Ii-Key/MHC class II epitope hybrids: a strategy that enhances MHC class II epitope loading to create more potent peptide vaccinesNikoletta L Kallinteris, Xueqing Lu, Catherine E Blackwell, et al.

International Archives of Allergy and Immunology|January 22, 2008

Single cell assessment of allergen-specific T cell responses with MHC class II peptide tetramers: methodological aspectsErik Wambre, Laurence Van Overtvelt, Bernard Maillère, et al.

Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:

Pageof 3

Vaccine|March 6, 2012

CD4+ T-cell activation for immunotherapy of malignancies using Ii-Key/MHC class II epitope hybrid vaccinesMinzhen Xu, Nikoletta L Kallinteris, Eric von Hofe

Cellular & Molecular Immunology|October 13, 2005

Forcing tumor cells to present their own tumor antigens to the immune system: a necessary design for an efficient tumor immunotherapyRobert E Humphreys, Gilda G Hillman, Eric von Hofe, et al.

Vaccine|June 13, 2009

Ii-Key/HPV16 E7 hybrid peptide immunotherapy for HPV16+ cancersMinzhen Xu, Xueqing Lu, Margaret Sposato, et al.

Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 8, 2005

Enhanced CD4+ T-cell response in DR4-transgenic mice to a hybrid peptide linking the Ii-Key segment of the invariant chain to the melanoma gp100(48-58) MHC class II epitopeNikoletta L Kallinteris, Shuzhen Wu, Xueqing Lu, et al.

Vaccine|July 15, 2009

Identification of HLA class II H5N1 hemagglutinin epitopes following subvirion influenza A (H5N1) vaccinationJohn W Zinckgraf, Margaret Sposato, Veronica Zielinski, et al.

Expert Opinion on Biological Therapy|December 10, 2008

CD4+ T cells in antitumor immunity: utility of an li-key HER2/neu hybrid peptide vaccine (AE37)Elizabeth A Mittendorf, Jarrod P Holmes, James L Murray, et al.

Immunology|November 23, 2006

Suppression of major histocompatibility complex class II-associated invariant chain enhances the potency of an HIV gp120 DNA vaccineXueqing Lu, Shuzhen Wu, Catherine E Blackwell, et al.

Vaccine|March 10, 2005

Linkage of Ii-Key segment to gp100(46-58) epitope enhances the production of epitope-specific antibodiesNikoletta L Kallinteris, Shuzhen Wu, Xueqing Lu, et al.

Expert Opinion on Biological Therapy|January 17, 2007

Ii-Key/MHC class II epitope hybrids: a strategy that enhances MHC class II epitope loading to create more potent peptide vaccinesNikoletta L Kallinteris, Xueqing Lu, Catherine E Blackwell, et al.

International Archives of Allergy and Immunology|January 22, 2008

Single cell assessment of allergen-specific T cell responses with MHC class II peptide tetramers: methodological aspectsErik Wambre, Laurence Van Overtvelt, Bernard Maillère, et al.

Pageof 3